ARTICLE SUMMARY:
The landmark CABANA trial has highlighted how one of the principal treatment strategies for atrial fibrillation, cardiac catheter ablation, still falls short. Industry—and clinicians—continue to believe that technological innovations are the answer. Companies with new catheter and imaging technologies think they can close the gap.
Atrial fibrillation (AF) is one of the most attractive segments in cardiology; Medtronic plc said so at its June 2018 investor and analyst day, describing a $4 billion market for cardiac catheter ablation with mid-teens growth rates.
